Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.

[1]  R. Damiano,et al.  Low-Dose Versus Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial , 2023, Annals of Thoracic Surgery.

[2]  L. Svensson,et al.  Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin. , 2021, The Journal of thoracic and cardiovascular surgery.

[3]  L. Svensson,et al.  Off-label Use of Direct Oral Anticoagulants in Patients Receiving Surgical Mechanical and Bioprosthetic Heart Valves , 2021, JAMA network open.

[4]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[5]  K. Anstrom,et al.  Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. , 2020, American heart journal.

[6]  D. Malenka,et al.  Tissue versus mechanical aortic valve replacement in younger patients: A multicenter analysis. , 2019, The Journal of thoracic and cardiovascular surgery.

[7]  J. Copeland,et al.  Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. , 2018, Journal of the American College of Cardiology.

[8]  A. Yoganathan,et al.  Clinical evaluation of new heart valve prostheses: update of objective performance criteria. , 2014, The Annals of thoracic surgery.

[9]  Chad Hughes,et al.  Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. , 2014, The Journal of thoracic and cardiovascular surgery.

[10]  J. Chambers,et al.  Clinical event rates with the On-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years. , 2013, The Journal of thoracic and cardiovascular surgery.

[11]  F. Verheugt,et al.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. , 2011, World journal of cardiology.

[12]  J. Mayer,et al.  Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Annals of thoracic surgery.

[13]  T. Holland-Letz,et al.  Single-center experience with the On-X prosthetic heart valve between 1996 and 2005. , 2007, The Journal of heart valve disease.

[14]  Kenneth Liu,et al.  Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials , 2006, Statistics in medicine.

[15]  M. Mack,et al.  North American multicenter experience with the On-X prosthetic heart valve. , 2006, The Journal of heart valve disease.

[16]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  A. Pipe,et al.  Late incidence and determinants of stroke after aortic and mitral valve replacement. , 2004, The Annals of thoracic surgery.